TheStreet.com Ratings provides exclusive stock, ETF and mutual fund recommendations using proprietary tools. Our "safety first" approach aims to reduce risk while achieving total return performance.BOSTON ( TheStreet) -- The following companies are projected to increase revenue and profit by at least 12% in the coming year and receive "buy"-ratings from our quantitative model, which considers more than 60 factors. They're ordered by their potential to appreciate, starting with the company with the best growth prospects. Lance ( LNCE) makes snack foods, including Cape Cod Potato Chips and Archway Cookies. The numbers: Second-quarter net income surged 252% to $9.5 million and earnings per share grew 233% to 30 cents, restrained by a higher share count. Revenue grew 11% to $237 million. Its gross margin jumped from 41% to 44% and its operating margin rose from 3% to 7%. A quick ratio of 1.1 indicates adequate liquidity. A debt-to-equity ratio of 0.4 demonstrates conservative leverage. The stock: Lance has advanced 14% in 2009, beating the Dow Jones Industrial Average and S&P 500 Index. The stock trades at a price-to-earnings ratio of 28, a premium to the market and packaged food peers. Shares pay a 2.4% dividend yield. Teva Pharmaceuticals ( TEVA) is an Israeli pharmaceutical company. The numbers: Second-quarter net income dropped 2% to $521 million and earnings per share fell 11% to 58 cents, hurt by a higher share count. Revenue ascended 20% to $3.4 billion. Its gross margin dropped from 58% to 54%, but its operating margin increased from 23% to 24%. A quick ratio of 0.9 indicates less-than-ideal liquidity. A debt-to-equity ratio of 0.4 reflects conservative leverage. The stock: Teva is up 18% this year, beating the Dow and S&P 500. The stock trades at a price-to-earnings ratio of 52, a premium to the market and pharmaceutical peers. Shares pay a 1.2% dividend yield.